Septerna soars on $2.2 billion Novo Nordisk deal

Septerna

14/05/2025 12:43

** Shares of drug developer Septerna SEPN.O rise 63.3% to $10.99 premarket

** Danish drugmaker Novo Nordisk NOVOb.CO is partnering with SEPN in a deal worth up to $2.2 bln to develop oral treatments for obesity and diabetes, the companies say

** Deal includes over $200 million in upfront and near-term payments to SEPN

** The firms plan to start four development programs for potential new therapies

** The partnership aims to create new medicines that target specific proteins to help with metabolism and other body functions, cos say

** As of last close, SEPN down 70.6% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))